Roche ‘talking to FDA’ as Alzheimer’s drug moves towards 2022 readoutPhase 3 results with Roche’s amyloid-targeting Alzheimer’s drug gantenerumab may not be due until the second half of Share XRoche ‘talking to FDA’ as Alzheimer’s drug moves towards 2022 readouthttps://pharmaphorum.com/news/roche-talking-to-fda-as-alzheimers-drug-moves-towards-2022-readout/
